View in web browser  |  Add to safe senders list
PR Week Follow us:
US Healthcare Newsletter  |  September 2nd 2014
 

The Food and Drug Administration has rescinded a partial hold on OncoMed Pharmaceuticals’ patient enrollments for three cancer-drug trials, the company said Thursday. The drug, vantictumab, is in Phase 1 clinical trials.

Reuters reported OncoMed’s stock jumped as much as 9% in early trading and noted that patient enrollment could pick up again following approval of revised trial protocol. Studies examined lung, breast, and pancreatic cancer patients.

According to FierceBiotech, Bayer paid $40 million upfront as part of a partnership begun in 2010 worth $430 million for “the right to buy in up to five drug candidates,” pending study results.

 

In other news:

 

 
Things you may have missed
 
1. Illinois gives FleishmanHillard $25.6m extension for Get Covered contract
 
2. Legacy gives teens social tools to advocate against smoking
 
3. Siegel+Gale study: Healthcare brands need to better connect with consumers
 
 

Top jobs of the month


To post a job on Careers.PRWeekUS.com click here.

PRWeek Careers brings you Careers.PRWeekUS.com : the best industry resource for landing your next career move. Careers.PRWeekUS.com delivers career-related news, expert advice, and the latest job openings in the industry. Upload your resume today and start taking advantage of all that Careers.PRWeekUS.com has to offer.

 
   

 
Manage Bulletins Unsubscribe